Insider Transactions in Q1 2025 at Collegium Pharmaceutical, Inc (COLL)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2025
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
30,426
-7.47%
|
$912,780
$30.52 P/Share
|
|
Feb 10
2025
|
Colleen Tupper EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
78,725
+16.74%
|
-
|
|
Feb 10
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,623
-8.64%
|
$888,690
$30.52 P/Share
|
|
Feb 10
2025
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,427
+17.97%
|
-
|
|
Feb 10
2025
|
Thomas B Smith EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,897
-3.19%
|
$176,910
$30.52 P/Share
|
|
Feb 10
2025
|
Thomas B Smith EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,075
+16.51%
|
-
|
|
Feb 10
2025
|
Michael Thomas Heffernan Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,820
+8.74%
|
-
|
|
Feb 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
34,975
-9.61%
|
$1,049,250
$30.52 P/Share
|
|
Feb 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
69,995
+16.84%
|
-
|
|
Feb 04
2025
|
Nancy Lurker Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,726
+50.0%
|
-
|
|
Jan 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
27,500
-9.73%
|
$907,500
$33.25 P/Share
|
|
Jan 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
27,500
+15.79%
|
$577,500
$21.34 P/Share
|